Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

NCT06161532 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

NIH

Sponsor class

Conditions

Small Cell Carcinoma of the Bladder
Small Cell Carcinoma of the Urinary Tract
Squamous Cell Carcinoma of the Bladder
Squamous Cell Carcinoma of the Urinary Tract
Primary Adenocarcinoma of the Bladder
Primary Adenocarcinoma of the Urinary Tract
Renal Medullary Carcinoma
Squamous Cell Carcinoma of the Penis

Interventions

DRUG: Sacituzumab govitecan
DRUG: Atezolizumab

Sponsor

National Cancer Institute (NCI)